Avicanna Inc ( (AVCNF) ) has released its Q3 earnings. Here is a breakdown of the information Avicanna Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avicanna Inc. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, with a focus on the global medical and pharmaceutical markets.
In its Q3 2025 earnings report, Avicanna Inc. highlighted continued revenue growth and strategic advancements, despite facing short-term margin pressures. The company emphasized its commitment to building a diversified and sustainable business model.
For the third quarter of 2025, Avicanna reported revenues of $6.40 million, with Canadian revenue increasing by 4% and international revenue rising by approximately 6%. The gross profit for the quarter was $3.15 million, resulting in a gross margin of 49%, which was impacted by non-recurring costs. The adjusted EBITDA loss stood at $0.79 million, reflecting a decrease compared to the previous year.
The company also achieved significant corporate milestones, including a 39% increase in Canadian sales units, the issuance of a U.S. patent for a topical cannabinoid composition, and the completion of its first export of CBD dominant cannabis flower to Switzerland. Additionally, Avicanna expanded its product offerings in the U.S. market through a partnership with Harrington Wellness.
Looking ahead, Avicanna remains focused on disciplined execution and delivering long-term value for shareholders, leveraging its scientific leadership and strategic collaborations to drive sustainable profitability.